Igg4-Treat R2: Identification Of Specific Serum Biomarkers And Immune Cell Dysregulation Commonly Associated With Igg4 Autoimmune Diseases (Msca Doctoral Network)

Universities and Institutes of France
January 31, 2024
Offerd Salary:Negotiation
Working address:N/A
Contract Type:Other
Working Time:Full time
Working type:N/A
Ref info:N/A

27 Oct 2023

Job Information


IgG4-TREAT (INSERM/Sorbonne)

Research Field

Biological sciences

Medical sciences

Researcher Profile

First Stage Researcher (R1)



Application Deadline

31 Jan 2024 - 23:59 (Europe/Vienna)

Type of Contract


Job Status


Hours Per Week


Is the job funded through the EU Research Framework Programme?


Marie Curie Grant Agreement Number


Is the Job related to staff position within a Research Infrastructure?


Offer Description

Short overview of the program:

IgG4-TREAT consortium is l ooking for highly motivated and talented PhD students to contribute to groundbreaking research in the field of IgG4-autoimmune diseases (IgG4-AID). The PhD researchers will have the opportunity to participate in a comprehensive training programme in academic and industry setup. Next to their transferable skills training, the IgG4-TREAT PhD students will pursue 10 individual, multidisciplinary research projects (organised into four scientific work packages) aimed to advance our understanding of IgG4-AID.

PhD candidates will become part of a network of 9 host laboratories and 7 associated partners from 7 different European countries. Funding for these projects has been provided by the EU under the competitive MSCA Doctoral Networks 2022 program (Grant Agreement No. 101119457). For more information on IgG4-TREAT visit our website: https: // www. igg4-treat.eu/.

Project R2: Identification of specific serum biomarkers and immune cell dysregulation commonly associated with IgG4 autoimmune diseases

Hosting lab + location:Dr Rozen Le Panse's Team at the Center of Research in Myology – INSERM/Sorbonne University – Hospital Pitié-Salpêtrière, Paris, France

Research project description:

IgG4 autoimmune diseases (IgG4-AID) are a group of severe autoimmunopathies that are characterized by pathogenic IgG4 autoantibodies against defined target antigens. To better understand IgG4-AID, we plan to identify specific serum biomarkers and immune cell dysregulation commonly associated with IgG4-AID.

Our team has a long-time expertise in autoimmune Myasthenia Gravis (MG) including MuSK MG mediated by IgG4 autoantibodies. The PhD project proposed in our laboratory will investigate serum biomarkers associated with IgG4-AID using the Olink technology that allows the analysis of at least 384 serum proteins per sample. In parallel, immune cell dysregulation in IgG4-AID will also be investigated by mass cytometry (CyTOF). These multiparametric analyses will be performed by comparing healthy donors with anti-MuSK-MG patients, but also anti-LGI1 encephalitis patients obtained from partners of the IgG4-AID network. Specific serum biomarkers and immune cell dysregulation will be further validated in other IgG4-AID by the PhD student during a secondment at TND (Tzartos NeuroDiagnostics, Greece) (ELISA and SIMOA analyses) or by different partners. In addition, the implication of defined immune dysregulation will be investigated by flow cytometry in the experimental MuSK-MG mouse models in a secondment at Istanbul University (supervised by V. Yilmaz and E. Tüzün, Turkey).

Methods used in the project: Mass and flow cytometry, Protein analyses (ELISA, SIMOA…), Bioinformatics skills for multiparametric analyses, Human blood sample preparation, Animal work during a secondment

Project duration: 36 months (35h/week)

Hosting lab description:

Dr Rozen Le Panse's team is part of the Center of Research in Myology located in Paris (hospital Pitié-Salpêtrière). She has been working on Myasthenia Gravis for more than 20 years. The team is investigating the etiological and pathophysiological mechanisms involved in MG. The team is also involved in the search for new therapeutic approaches using different experimental models. In collaboration with clinicians working on Myasthenia Gravis, the team is also looking for new cellular and molecular biomarkers for the follow-up of the patients using new technological approaches. More information on Le Panse's team.

Foreseen mobility: Secondments are planned in:

  • TND (Tzartos NeuroDiagnostics, supervised by S.Tzartos, Greece): Validate Olink findings using SIMOA technology.
  • Istanbul University (supervised by V. Yilmaz and E. Tüzün, Turkey): Analyze immune cell dysregulation in IgG4-AID active immunization mouse model (MuSK MG).
  • Requirements

    Research Field

    Biological sciences

    Education Level

    Master Degree or equivalent

    Research Field

    Medical sciences

    Education Level

    Master Degree or equivalent


  • Qualification in immunology
  • Good skills in flow cytometry, data analysis with an affinity for bioinformatics
  • Good level of spoken and written English
  • Languages



    Additional Information


    The funding is guaranteed for 36 months and will include:

  • a monthly living allowance of 3,400 EUR/month (gross salary will be adjusted through the application of a country correction coefficient for the country in which the researcher is recruited; as indicated in Table 1 of the MSCA Work Programme)
  • a monthly mobility allowance of 600 EUR/month;
  • a monthly family allowance (if applicable), of 660 EUR/month.
  • Allowances are gross amounts , which means that all compulsory social security contributions, direct taxes, and any other compulsory deductions under national legislation will be deducted from these amounts.

    Eligibility criteria

  • Applicants must not have resided or carried out their main activity (work, studies, etc.) in the host country for more than 12 months in the 36 months immediately preceding the starting date of the PhD (earliest starting date: 31/03/2024) ( MSCA Mobility Rule ).
  • At the time of the deadline, applicants must not be in possession of a doctoral degree or have successfully defended their doctoral thesis awaiting formal notification.
  • At the time of enrolment, applicants must be eligible for enrolment for PhD studies at the hosting institution.
  • Selection process

    How to apply:

    Interested candidates can find more information on the consortium website. Candidates can apply for up to three positions and should indicate their preferences in the application form. To apply, please send the following application documents as a single PDF file to [email protected]. As the subject of your email, please use IgG4-TREAT application-your last name.

  • Application Form (available for download on the consortium website https: // www. igg4-treat.eu/apply)
  • CV (in Europass or ORCID format) including any publications, prizes/grants obtained, and international experience. The candidates are asked to highlight any extra-professional activities to measure leadership, creativity, communication abilities, etc. as well as their hobbies.

  • Motivation letter : 1 page highlighting the main expertise of the applicant, career plans and motivations for the program.

  • Copy of transcripts and diploma(s) for the obtained degree(s). If the degree is imminent, but not yet obtained, a letter from the University delivering the degree must be included.
  • Contact details (e-mail address and phone number) to possible referees - direct research supervisor(s) at current (or last) university at the time of enrolment.
  • Copy of an ID or Passport
  • All documents need to be provided in English. We aim for a maximum level of inclusiveness in our recruitment, and to reduce the risk of any bias, we ask that candidates focus only on their academic qualifications and make sure that no information on biological sex, gender identity, age, ethnicity, or sexual orientation is included in the application documents (with the exception of the application form).

    Recruitment procedure:

    The selection procedure will be open, transparent, merit-based, and in line with the Code of Conduct for the Recruitment of Researchers. All the network institutions are equal opportunity employers and seek a workforce diverse in age, culture, nationality and gender.

    The application process will start in October 2023. The deadline for applications is 31/01/2024. The individual projects are set to start between 31/03/2024 and 01/09/2024.

    The selection process will consist of several steps. First, we will check if the applications are complete and if the applicants fulfill the eligibility criteria. Then, each eligible application will be evaluated by the prospective supervisors, according to project preferences indicated by the applicant. Shortlisted candidates will be invited for the next steps of the application process including several rounds of online interviews with prospective supervisors and other supervisors from the network. Successful candidates will be informed within a few weeks after the interviews.

    Website for additional job details

    https: // www. igg4-treat.eu/apply/

    Work Location(s)

    Number of offers available



    Center of Research in Myology – INSERM/Sorbonne University, Paris, France





    Postal Code



    105 Boulevard de l'Hôpital


    Where to apply


    https: // www. igg4-treat.eu/apply/





    https: // www. igg4-treat.eu/

    https: // recherche-myologie.fr/research/labs/le-panse- lab/?lang=en#tabsequipe1


    105 Boulevard de l'Hôpital

    Postal Code



    [email protected]


    From this employer

    Recent blogs

    Recent news